Covid Risk Articles & Analysis
42 news found
Fresh air helps to push out virus-filled air from a room, reducing the risk of COVID-19 as long as other safety measures like masking and social distancing are followed. ...
ByZeptive
The granted R&D project is 'Development of sublingual COVID-19 subunit vaccine,' in which CHA Vaccine Institute, PanGen Biotech, and BioLingus will develop a sublingual tablet or drop type of recombinant subunit COVID-19 vaccine. ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. ...
The Phase 3 trial, which began in the US earlier this year, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. ...
ByVaxxinit
The study, “Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the Emergency Department setting,” demonstrated that the IntelliSep test has the potential to rapidly risk-stratify patients independent of pathogen, an important finding as risk stratification may improve resource ...
Lilly has submitted a request for an EUA for bebtelovimab for the treatment of mild to moderate COVID-19 in certain high-risk patients to the FDA. Details regarding Lilly's agreement to provide the U.S. government with up to 600,000 doses no later than March 31, 2022, with an option of 500,000 additional doses no later than July 31, 2022, can be found here. ...
Inflammation plays a critical role across all diseases, from infectious diseases like COVID-19 and other respiratory illnesses to diseases like cancer. In COVID-19, the body triggers an inflammatory response that produces proteins including CRP and IP-10 or CXCL-10, which are markedly elevated in hospitalized COVID-19 patients. Preliminary data ...
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source. This ...
After receiving the second order of 100 more Robots from the European Commission in September following the first order of 200 Robots in 2020 UVD Robots has entered a global partnership agreement with OCC Commercial Consulting to combat COVID-19 and high-risk pathogens commonly found in grocery, food service and retail environments. ...
These gaps make it harder for hospitals to make informed decisions about infection prevention and put both staff and patients at risk. The recent COVID-19 pandemic highlights just how critical timely intervention is for individual hospitals and the overall public health. ...
ByBioVigil
![Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyMjk0OC9pbWFnZXMvMTIyOTQ4XzBfMjAyMjEyMDQwNTU2Mzk0NjQwMjcxXzQwMC5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MjQwLCJoZWlnaHQiOjE0NX19fQ== "Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients")
The goal is to enable innovative approaches to the diagnosis and treatment of COVID-19 patients and thus improve patient care. The COVID-19 pandemic has crippled the world since 2020, with more than 190 million infections and more than 4 million deaths now reported. However, the state of knowledge about the disease is still insufficient, especially in terms of ...
The guidance, in the form of Frequently Asked Questions, aimed at a non-specialist audience is available on the Society’s COVID-19 hub, alongside guidance on managing COVID risk in different sectors and guidance on managing other health risks, such as legionella, as the economy opens up. ...
The Society draws attention to research by Oxford University Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine | University of Oxford that highlights that asymptomatic infection is still an appreciable risk after receipt of vaccinations. ...
"Today marks one year since the WHO officially declared the COVID-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19." ...
ByNovavax
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. ...
The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. ...
A Rutgers scientist has invented an early treatment for COVID-19 to prevent severe complications and hospitalizations in patients with prediabetes and diabetes by increasing beneficial bacteria in the gut and reducing organisms that cause coronavirus. ...
With adjustments in line with governmental guidelines at our factory we have become a Covid-Secure workplace which will allow us to continue to operate throughout the pandemic and minimise the risks of COVID-19 to our on-site employees. ...
The disruptive impact of the Covid-19 pandemic on medical services has been a central concern across our industry. ...
The Risk Matrix BOHS-Covid-19-Control-Measures-Risk-Matrix-Version-1.0_23.07-1.pdf the Society issued last year remains its definitive statement of appropriate precautionary measures to protect against the risk of COVID-19 infections in the workplace. ...